norethindrone drug combination estradiol

05/01/2000 - "The incidence of bleeding anomalies was higher in the Mesigyna group, with a discontinuation rate for these reasons of 20% versus 4% for IUD (p <0.05). "
03/01/1995 - " These findings show that Mesigyna users experienced better cycle control and more acceptable bleeding patterns than did the users of the other two injectables."
05/01/2000 - "The duration of bleeding days as well as dysmenorrhea were less with Mesigyna. "
03/01/1995 - " Acceptability of bleeding patterns was much higher among Mesigyna users than Cyclofem users (p 0.001). "
04/01/1994 - "Prolonged bleeding is also more common in Cyclofem and Mesigyna users (13.3% and 11.1%, respectively vs. 2.3%). "

08/01/1999 - "Discontinuation rates because of amenorrhea were 2.74 in the Cyclofem group compared to 1.38 in the Mesigyna group, whereas the rates of discontinuation because bleeding problems were significantly higher among Mesigyna users (11.54) compared to the Cyclofem group (7.39). "
01/01/1988 - "Discontinuations for bleeding irregularities were low, being 6.3% and 7.5% for HRP112 and HRP102 respectively, as well as for 'amenorrhea', the respective figures being 2.1% and 1.6%. "
04/01/1996 - " Two combined injectable preparations--Cyclofem and Mesigyna--are now available in many countries and associated with a significant reduction in both amenorrhea and unacceptable bleeding rates. "
03/01/1995 - "Discontinuation rates for bleeding problems were significantly different between the groups: discontinuation rates for amenorrhea were 0.58%, 3.71% and 0.68% (p < 0.001) for Mesigyna, Cyclofem and Injectable No. 1; for other bleeding problems, the rates were 4.88%, 8.38% and 12.64% (p < 0.001). "
04/01/1994 - "Researchers find lower 12-month life table discontinuation rates for menstrual disturbances for Cyclofem (2.1-5.2% for amenorrhea and 6.3-12.7% for bleeding related reasons) and Mesigyna (0.8-4.2% for amenorrhea and 7.5-12% for bleeding related reasons) than expected for most progestogen-only methods. "

03/01/1995 - " Cyclofem users had more spotting days than did Mesigyna users in each 90-day period (5-8 vs. 5-6). "
05/01/1985 - "The percentage of days with bleeding and spotting was 24% for Cycloprovera and 29% for HRP-102. "
03/01/1995 - "Relative to users of Mesigyna or Cyclofem, Injectable No. 1 users had 2-3 more bleeding/spotting days, and a shorter length of bleeding/spotting-free intervals in each period. "
03/01/1995 - "Thereafter, 50% of Mesigyna users had precisely 3 bleeding/spotting episodes every 90 days, 50% of Cyclofem users had 2-3 and 50% of Injectable No. 1 users had 3-4 episodes every 90 days. "
03/01/1995 - "The number of bleeding/spotting days over four periods showed little difference between the two group, but there were more spotting days and there was greater individual variability among Cyclofem users.(ABSTRACT TRUNCATED AT 250 WORDS) Between October 1988 and July 1990, a randomized multicentered phase III clinical trial was conducted in three provinces of China to compare three monthly injectable contraceptives (Mesigyna [50 mg norethisterone enanthate + 5 mg estradiol valerate], Cyclofem [25 mg medroxyprogesterone acetate + 5 mg estradiol cypionate], and Injectable No.1 [250 mg 17-hydroxyprogesterone caproate + 5 mg estradiol valerate]). "

05/01/2000 - "Mean weight gain after one year of use was 1.02 kg. Mesigyna is an appropiate once-a-month injectable contraceptive for Latin American women since it is highly effective and its perception of normal menstrual bleeding is of importance in the Latin American population."

05/01/2000 - "The duration of bleeding days as well as dysmenorrhea were less with Mesigyna. "